Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0016382 (flushing)
 6,387 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Ovulation rate was measured by laparoscopy at two consecutive cycles on 366 ewes 2 yr old and over and 85 yearling ewes of five lines of Targhees from the base base population; 53 yearling linecross ewes were also included. The lines were two unselected controls (HCl and DC), two selected for 21 yr for increased 120-d weight (HW and DH) and one selected for 19 yr for multiple births (T). Ewes were synchronized in late July or early August at the start of the normal breeding season with intravaginal pessaries impregnated with 60 mg methylacetoxyprogesterone and examined at first and second estrus. Ovulation had occurred in both cycles in 327 (89%) and 177 (85%) of the mature and yearling ewes, respectively. Overall mean numbers of corpora lutea at first and second estrus were 1.42 and 1.63, respectively for ewes 2 yr and over and 1.20 and 1.44 for yearlings, indicating an effect of synchronizing treatment, season, flushing, or a combination of these. Among mature ewes, ovulation rate was higher (P less than .05) in DH (+.20), HW (+.19) and T (+.16) than in controls at first estrus, and in HW (+.29) and T (+.21) but not DH (-.04) at second estrus. Among yearlings, differences were significant only at second estrus (HW, +.40; T, +.35) and again not for DH (+.08). The failure of line DH to increase in ovulation rate from first to second estrus as did other lines was transmitted to linecross progeny. Body weight within line affected ovulation rate significantly, with a greater effect at second estrus, in both age groups. Adjustment for body weight removed the difference between HW and controls but not between T and controls. Repeatability of corpora lutea count was .27 and .25 for mature and yearling ewes, respectively.
J Anim Sci 1985 Dec
PMID:Ovulation rate in sheep selected for weaning weight or litter size. 408 91

Uterine flushings collected from mares before and after bacterial-induced inflammation were assayed for ability to opsonize Streptococcus zooepidemicus for phagocytosis by polymorphonuclear leukocytes. Opsonization was measured as the peak phagocytic rate of bacteria preincubated with uterine flushings relative to the peak phagocytic rate of unopsonized bacteria. Flushings from four mares with noninfected uteri were unable to opsonize bacteria regardless of whether uteri were flushed at estrus or on day 10 postovulation. In a second experiment, 7 X 10(9) live S. zooepidemicus were inoculated into the uterus of five mares during estrus. Uterine flushings collected at the estrus before inoculation or at the estrus after inoculation did not opsonize bacteria. Four of five flushings collected 6 hr post inoculation, however, were capable of opsonization. Based on heat inactivation at 56 degrees C, the opsonizing activity of one of four flushes was due to a complement protein. It was concluded that one aspect of the acute inflammatory response of the mare's uterus is accumulation of opsonins in the uterine lumen.
Am J Reprod Immunol Microbiol 1985 Dec
PMID:Opsonization of bacteria by uterine secretions of cyclic mares. 409 Nov 70

Flushing fluid from microsponges (surgical spears) and solutions for irrigation (balanced salt solution and Ringer solution) as well as other medicaments for intraocular use during surgery (solutions of Zolyse, solutions of Miochol and Healon) have been examined for particulate contamination. The method used to collect and analyse the particles involved scanning electron microscopy (SEM) and energy dispersive analysis of X-ray (EDAX) in order to determine elements within the range of atomic number 9-93 in the periodic system. The investigation disclosed particulate contamination of all solutions examined. Particle number (greater than 5 microns) per ml varied from 15 to 400 and the size from 5 microns-800 microns. Microsponges released particles in numbers from 25-90 in a size range of 5-3000 microns per ml flushing fluid (Total flushing volume 20 ml). More than half of the particles were below 10 microns in all specimens examined. The irrigation solutions and solutions of medicaments contained only few particles above 40 microns. Most of the particles were of organic material which is not detectable with EDAX. This analytical system disclosed a wide range of inorganic elements, being present in the examined solution in the form of particles or as solutes.
Acta Ophthalmol (Copenh) 1985 Dec
PMID:Particulate contamination in eye surgery. 409 4

A system using totally disposable self-supporting bedpans requiring no carrier was examined in use in two hospitals. The bedpans and their contents were disposed of by destruction and flushing to waste carried out in a modified Haigh Sluicemaster disposal unit. This incorporates a positively closing and locking lid with refinements to avoid the lid slamming and has effective safety devices. The new bedpans and the improved disposal units reduce the risk of transfer and dispersal of pathogenic organisms to an acceptable level in ward and sluice room.
J Clin Pathol 1973 Dec
PMID:A disposable bedpan system using an improved disposal unit and self-supporting bedpans. 478

A simple method has been developed that allows frozen thin sections of fresh-frozen tissue to be cut on a virtually unmodified ultramicrotome kept at room temperature. A bowl-shaped Dewar flask with a knifeholder in its depths replaces the stage of the microtome; a bar extends down into the bowl from the microtome's cutting arm and bears the frozen tissue near its lower end. When the microtome is operated, the tissue passes a glass or diamond knife in the depths of the bowl as in normal cutting. The cutting temperature is maintained by flushing the bowl with cold nitrogen gas, and can be set anywhere from about -160 degrees C up to about -30 degrees C. The microtome is set for a cutting thickness of 540-1000 A. Sections are picked up from the dry knife edge, and are placed on membrane-coated grids, flattened with the polished end of a copper rod, and either dried in nitrogen gas or freeze-dried. Throughout the entire process the tissue is kept cold and does not come in contact with any solvent. The morphology seen in frozen thin sections of rat pancreas and liver generally resembles that in conventional preparations, although freezing damage and low contrast limit the detail that can be discerned. Among unusual findings is a frequent abundance of mitochondrial granules in material prepared by this method.
J Cell Biol 1971 Dec
PMID:Frozen thin sections of fresh tissue for electron microscopy, with a description of pancreas and liver. 494 76

The effects of 9 beta-methyl carbacyclin, a chemically stable analogue of epoprostenol (prostacyclin, PGI2) were studied, in comparison with epoprostenol, both in vitro and in vivo in man. In vitro 9 beta-methyl carbacyclin and epoprostenol inhibited platelet aggregation induced by ADP, collagen, the endoperoxide analogue U46619 and arachidonic acid. The potency of 9 beta-methyl carbacyclin relative to epoprostenol was comparable in ADP and collagen-aggregated platelet rich plasma (PRP), 9 beta-methyl carbacyclin being 0.01 times as active as epoprostenol. The anti-aggregatory potencies of the two compounds were comparable in PRP and whole blood. The phosphodiesterase inhibitor isobutyl methyl xanthine enhanced the anti-aggregatory activity of both compounds in vitro. 9 beta-methyl carbacyclin and epoprostenol elevated platelet cyclic AMP, 9 beta-methyl carbacyclin being 0.04 times as active as epoprostenol. In a placebo controlled trial both drugs produces significant headache and facial flushing when compared with placebo. Nasal stuffiness, abdominal discomfort and nausea were reported on all three treatments. Both drugs caused significant and comparable increase in heart rate and decrease in pre-ejection (PEP) and PEP/left ventricular ejection time (LVET) ratio compared with placebo. Systolic and diastolic blood pressure, LVET and QS2 index were unchanged. Platelet aggregation responses to ADP were significantly inhibited by all three doses of both drugs compared with placebo. Bleeding time was significantly longer during epoprostenol infusion than either placebo or 9 beta-methyl carbacyclin infusion. Neither drug had significant effect, compared with placebo, on kaolin activated clotting time in PPP, PRP or in PRP in the presence of heparin, prothrombin time, partial thromboplastin time, thrombin clotting time, fibrinogen, fibrinogen degradation products or euglobulin clot lysis time. The pharmacodynamic effects and duration of action of 9 beta-methyl carbacyclin and of epoprostenol are similar; 9 beta-methyl carbacyclin is approximately 100 times less potent than epoprostenol in man.
Br J Clin Pharmacol 1984 Dec
PMID:A chemically stable analogue, 9 beta-methyl carbacyclin, with similar effects to epoprostenol (prostacyclin, PGI2) in man. 608 4

Eighteen postmenopausal women with severe hot flashes had continuous recordings of finger temperature and skin resistance as objective indexes of flushing episodes, and serial measurements of anterior pituitary hormones as indirect indexes of hypothalamic neurotransmitter activity. Significant increases of growth hormone, adrenocorticotropic hormone (ACTH), and luteinizing hormone (LH) occurred with maximal concentrations at 30, five, and 15 minutes, respectively, after the onset of the skin temperature rises. No significant fluctuations of prolactin (PRL), thyroid-stimulating hormone (TSH), or follicle-stimulating hormone (FSH) were observed. The mean serum cortisol concentration increased 15 minutes after the hot flash, presumably consequent to the preceding elevation of ACTH. Pituitary ACTH release may be secondary to hypothalamic cooling, whereas increased growth hormone and LH output and the thermoregulatory adjustments comprising the flushing episodes are all consistent with cyclic episodes of increased hypothalamic norepinephrine activity.
Obstet Gynecol 1984 Dec
PMID:Pituitary hormones during the menopausal hot flash. 609 54

The effects of synthetic cyclic somatostatin 14 were studied in two patients with the carcinoid syndrome. The 3-hour intravenous administration of somatostatin (250 micrograms X h-1), a) resulted in the disappearance of flushing in the first patient but was without any clinical effect in the second subject who remained chronically colored; b) lowered plasma levels of motilin, prostaglandins (E1, E2 and F2 alpha) and to a lesser extent of catecholamines in both patients whereas the serotonin level was not altered; c) was followed by a rebound effect with recurrence of severe flushing in the first patient and was associated with a dramatic increase of prostaglandin, substance P and catecholamine levels in both patients. The inhibitory effect of somatostatin and the occurrence of a rebound effect at the end of infusion were confirmed by infusing somatostatin (6 mg per day) during 48 h in the first patients. These results: a) show that somatostatin is an effective drug in carcinoid syndrome with severe flushing; b) confirm that several mediators are affected in carcinoid syndrome. However it could not be excluded that increased circulating levels of prostaglandins, substance P and catecholamines may represent unrelated secondary events; c) suggest that somatostatin primarily inhibits the release rather than the synthesis of tumor products. Owing to the severity of the rebound effect, treatment of the carcinoid syndrome with somatostatin must be undertaken with precaution until specific long-acting analogs are available.
Gastroenterol Clin Biol 1983 Dec
PMID:[Effects of the administration of somatostatin 14 in the carcinoid syndrome. Clinical and biological study of 2 cases]. 614 Nov 19

33 patients with advanced malignant melanoma were studied after intravenous administration of 131I-labeled Fab fragments specific for p97, an oncofetal glycoprotein of human melanoma. In all, 47 gamma camera imaging studies were performed for the purpose of localization of metastatic deposits. In addition to tumor, 131I-Fab uptake was also seen in liver and kidney. 20 of these studies included simultaneous administration of both an 131I-labeled Fab specific for p97, and an 125I-labeled Fab not specific for p97. Blood clearance of p97-specific Fab was significantly more rapid than for nonspecific Fab. Eight of these patients had biopsies of subcutaneous nodules at 48 and 72 h postinjection in order to assess whether localization of radioactivity was antigen specific. Antigen-specific localization was observed with average ratios of specific/nonspecific uptake of 3.7 (48 h) and 3.4 (72 h); uptake was strongly correlated with tumor p97 concentration (r = 0.81, P less than 0.01). Also, imaging studies of the bio-distribution of 131I-labeled anti-p97 Fab in patients selected for high p97 tumor concentration showed avid tumor uptake and more prolonged retention of labeled Fab in tumor than in normal tissues. Based on these studies, we estimated that total 131I doses of 500 mCi could be safely given to patients before dose-limiting toxicity would be observed. Accordingly, in seven selected patients, phase I radiotherapeutic trials were begun. For improved radiation safety, we developed automated methods to label Fab fragments with up to 200 mCi of 131I. So far, a total of 12 individual therapeutic doses, ranging from 34 to 197 mCi of 131I-labeled to 5 to 10 mg of Fab, have been administered with excellent tumor localization and without major target organ toxicity. Cumulative doses ranged from 132 to 529 mCi 131I. Side effects attributable to the radiation were mild, with a transient drop slightly greater than 50% in platelet and absolute neutrophil counts being observed in the two patients who received cumulative doses greater than 500 mCi. In the combined series of 47 diagnostic and 12 therapeutic studies, four acute reactions were observed: one episode each of transient chills and fever; flushing and hypotension; and two skin rashes. All of these reactions responded promptly to symptomatic therapy. After multiple administrations of 131I-(anti-p97) Fab (IgG1), isotype-specific immunity was observed in three patients. In two of these patients it was possible to successfully reinfuse after immunity had developed with 131I-(anti-p97) Fab of a different isotype (IgG2a). Dosimetry estimates were performed based on the biodistribution of (131)I-Fab in these patients,and for every 100 mCi of (131)I-Fab given, tumor receives 1,040 rads; liver. 325 rads; and bone marrow, 30 rads. Marrow would be expected to be the critical organ, if doses >500 mCi (131)I-Fab are given. These studies demonstrated that, with proper precautions, large doses (of an (131)I-labeled murine Fab fragments immunologically specific for a human melanoma-associated antigen) could be safely given to humans by using repetitive intravenous injections.
J Clin Invest 1983 Dec
PMID:Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. 619 80

Epoprostenol (prostacyclin, PGI2) was given intravenously to seven healthy volunteers in a dose of 4 ng kg-1 min-1 over a 30 min period. Diastolic blood pressure fell but there was no change in cardiac output. The mean PGI2 concentration at the end of the infusion was 0.43 ng/ml (1.1 nM) and a significant inhibition of ADP-induced platelet aggregation occurred. Although obvious facial flushing occurred in all subjects and some subjects complained of headache, cerebral blood flow tended to fall. The results do not support the hypothesis that PGI2 acts as a physiological vasodilator involved in the homeostasis of normal cerebral blood flow.
Br J Clin Pharmacol 1983 Dec
PMID:The effect of intravenous epoprostenol (prostacyclin, PGI2) on cerebral blood flow and cardiac output in man. 636 96


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>